Alongside antibody discovery and TAO ... human colon cancer by binding specifically and with high efficacy to the GPCR and immuno oncology target ADAORA2A 4. “Our vetted array of lead antibodies ...

Now, thanks to advances in structural biology, several of which earned Nobel prizes, a new generation of more selective GPCR-targeted drugs is within reach. Not surprisingly, this has led to ...

LifeArc Ventures is leading a $16 million (£13 million) Series A financing of Maxion Therapeutics (PDF), together with Monograph Capital and BGF. Put together by industry veteran Dr John ...